ALLO News and Press, Allogene Therapeutics Inc. From 01/05/24

2024-01-05 07:43:11 ET Allogene Therapeutics ( NASDAQ: ALLO ) fell ~22% premarket Friday after the cell therapy developer announced a pipeline shakeup that it said would cut costs and reduce cash burn. As part of the strategy named 2024 Platform Vision, the company will depr...

Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology comp...

Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR T Large B-Cell Lymphoma (LBCL) : Groundbreaking ALPHA3 Trial has Potential to Leapfrog Other CAR Ts and Embed Cemacabtagene Ansegedleucel (Cema...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™ ) products for cancer, today announced that it will host a conference call to pr...

Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile Comparable to Approved Autologous CAR T Therapies Company Received Fast Track Designation for A...

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming invest...

2023-11-24 06:40:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are many ways to approach penny stocks , but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.&#...

2023-11-03 13:17:21 ET More on Allogene Therapeutics Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Allogene Therapeutics Historical earnings data for Allogene Therapeutics Financial information for ...

Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ Cells Data from Preclinical Study of Cloak™ Technology Highlights Ability to Engineer Allogeneic Cells to Evade Detection by the Ho...

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutic...